Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people begin to notice semaglutide's effects within the first one to four weeks of treatment, though meaningful weight loss typically builds over several months. The STEP 1 trial, published in the New England Journal of Medicine, found that participants taking 2.4mg semaglutide lost an average of around 15% of their body weight over 68 weeks — a result that reflects a gradual, cumulative process rather than a sudden change. Semaglutide is a prescription-only medicine, and a prescriber will assess whether it is suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial is the clearest window we have into semaglutide's timeline. Over 68 weeks, adults with obesity taking 2.4mg semaglutide alongside lifestyle support achieved an average weight reduction of approximately 15%, compared with around 2.4% in the placebo group. What the headline figure doesn't show is the shape of that journey: weight loss started slowly, picked up as the dose was increased, and continued accumulating well past the six-month mark.
In the early weeks, the effects people notice first are not always about weight at all. Reduced appetite, a faster sense of fullness after smaller portions, and sometimes a shift in how much certain foods appeal to you, these are the GLP-1 receptor effects working before the scales have much to report. For some people, nausea or mild digestive discomfort appears in the same window. This is common and usually settles as the body adjusts, particularly if the dose is kept low at the start.
The starting dose of 0.25mg is specifically designed to give the body time to adapt, not to produce rapid weight loss. Expecting dramatic results at this stage sets the wrong benchmark. Patience in the early weeks is genuinely part of how the medicine works.
Semaglutide reaches what pharmacologists call steady-state blood levels after about four to five weeks of weekly injections. That matters because the therapeutic effect tracks those levels, the fuller appetite suppression tends to emerge once the medicine has been present consistently, not after the first or second injection alone.
The licensed titration pathway moves through 0.25mg, 0.5mg, 1.0mg, 1.7mg, and then 2.4mg, with roughly four weeks at each level guided by the prescriber. Many people report that the shift from the lower starter doses to the mid-range doses is when the effect becomes noticeably stronger. That step usually falls somewhere around weeks eight to twelve for those who tolerate each increase well.
Understanding this rhythm helps set realistic expectations. The NHS semaglutide medicines page explains the titration schedule clearly and is worth bookmarking alongside your treatment. A prescriber (not a fixed rule) decides the pace of increases based on how you are tolerating each dose.
For most people, consistent, week-on-week weight loss becomes more predictable from around month three onwards, once a meaningful therapeutic dose is in place. Before that, the pattern can feel uneven: a good week followed by a plateau, then movement again. This is normal and reflects the body's adaptation, not a sign the medicine is failing.
Protein intake, hydration, and regular movement all influence how well the medicine's appetite effects translate into fat loss rather than muscle loss. These are not add-ons; the trial evidence was collected alongside lifestyle support. A prescriber or dietitian can help you think through what that looks like practically, keeping a routine helps, whether that means your injection on the same evening each week, stored in the fridge door where you'll see it.
If you're thinking about what to expect over the longer term, the page on how long Wegovy takes to work covers the full treatment arc in detail, and our Wegovy treatment guide explains eligibility and the overall programme.
There is a meaningful difference between a slow start (which is expected) and a medicine that genuinely isn't working for you. The NICE appraisal of semaglutide (TA875) notes that if less than 5% weight loss has occurred after six months at the maintenance dose, continuing treatment should be reviewed. That review is a clinical conversation, not an automatic stop.
Separately, there are symptoms that need prompt attention at any point: severe stomach pain that spreads to your back, persistent vomiting preventing you from keeping fluids down, or signs of an allergic reaction. These are not about slow effects, they are reasons to seek medical help without delay and to report the experience via the MHRA Yellow Card scheme.
If you have questions about your individual response, or you're wondering whether semaglutide is right for you in the first place, our prescribers are available seven days a week. Many patients also find it helpful to read about how long it takes to feel the effects of Wegovy, understand how long before you feel the effects of Wegovy at each dose stage, and get a clearer picture of how long until the effects of Wegovy become noticeable for most people. You can read more about how Wegovy may affect blood test results if that is also on your mind, or explore weight-loss treatment options more broadly. When you're ready, speak to our prescribers through a free consultation, a real clinician reads your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.